Research programme: antibodies - Enleofen

Drug Profile

Research programme: antibodies - Enleofen

Alternative Names: Cytokine antibody - Enleofen; Receptor antibody - Enleofen

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke-NUS Graduate Medical School Singapore; National Heart Centre Singapore
  • Developer Enleofen
  • Class Antibodies; Antifibrotics; Cardiovascular therapies
  • Mechanism of Action Interleukin 11 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 14 Nov 2017 Preclinical trials in Fibrosis in Singapore (unspecified route)
  • 04 Apr 2017 Antibody therapeutics and over five patent applications licensed to Enleofen
  • 04 Apr 2017 Enleofen has patent protection for antibody therapeutics for the treatment of cardiovascular fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top